LB Pharmaceuticals

tenant

drug

BXCL501 Sublingual Film

as of 2026-07-01

Add to landscape Monitor this Compare this Ask about this

at a glance

small molecule

Pre-approval / investigational in the US

Developed by BioXcel Therapeutics Inc

1 trials in the graph

Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality

small molecule

Indications

Investigational (via trials)

Schizophrenia Schizophreniform Disorders Bipolar Disorder Psychomotor Agitation Schizophrenia Bipolar II Disorder Psychomotor Agitation Psychotic Disorders Bipolar I Disorder Schizoaffective Disorder

Trials

1

Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder

NCT07116694Phase 2Completed

KOLs & investigators

1

Matt Mandel, MD

Facts & assertions

0 sourced

No assertions recorded for this entity.

relationships

The graph out of here

developer

BioXcel Therapeutics Inc

company

trial

Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder

PHASE2

trial

indication

indication

Schizophreniform Disorders

indication

Bipolar Disorder

indication

Psychomotor Agitation

indication

KOL

Matt Mandel, MD

KOL score —

person